Art. -Nr.: HY-129630

Tetrahydrocortisol

Kundenbewertung

Based on 1 Customer Validation

Tetrahydrocortisol is a metabolite of Hydrocortisone (HY-N0583) that fails to activate glucocorticoid receptor. Tetrahydrocortisol inhibits Dexamethasone (HY-14648)-induced formation of cross-linked actin networks. Tetrahydrocortisol acts as a synergist to enhance the activity of anticancer agents. Tetrahydrocortisol can be used in the research of primary open-angle glaucoma, ocular hypertension, lung cancer and breast cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.91%
CAS. Nr.: 53-02-1
Formel: C₂₁H₃₄O₅
Molecular Weight:366.49

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Tetrahydrocortisol Chemical Structure

CAS. Nr.: 53-02-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Human Endogenous Metabolite

In Vitro

Tetrahydrocortisol (0.01-1 μM; 2-14 days) inhibits dexamethasone-induced formation of actin cross-linked networks in human primary trabecular meshwork cells, with an IC₅₀ of 0.57 μM after 14 days of treatment. When used alone, it increases microfilament bundling and partially reverses dexamethasone-induced microtubule disorganization^[1].
Tetrahydrocortisol (5-500 μM; 24 h) exhibits extremely weak cytotoxicity against EMT-6 mouse breast tumor cells, yet at 100 μM for 24 h, it protects normoxic EMT-6 cells from the cytotoxic effects of various anticancer agents and X-rays. Its protective effect is attenuated under acidic pH or hypoxic conditions^[2].
Tetrahydrocortisol (0.1 mM; 48 h) slightly increases the packed cell volume of quiescent SM-C1 fibroblasts isolated from rat carrageenan granulomas, and simultaneously induces minor changes in the content and distribution ratio of intracellular free amino acids^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tetrahydrocortisol (125 mg/kg; s.c.; continuous infusion; 14 days) alone produces a modest 0.6-day tumor growth delay in Lewis lung carcinoma-bearing mice, reduces CDDP (HY-17394) and Melphalan (HY-17575)-induced tumor growth delay, enhances Cyclophosphamide (HY-17420) and radiation-induced tumor growth delay, and does not affect lung metastasis number or size when administered alone or with cytotoxic therapies^[2].
Tetrahydrocortisol (125 mg/kg; s.c.; continuous infusion; 14 days) in combination with β-Cyclodextrin tetradecasulfate (HY-107201) and minocycline (HY-17412A) produces a 1.2-day tumor growth delay alone, greatly enhances cytotoxic therapy-induced tumor growth delay, reduces the percentage of large lung metastases when administered alone, and further reduces lung metastasis number and size when combined with most cytotoxic therapies^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL (8-10-week-old male; s.c. implantation of 2 × 10⁶ Lewis lung carcinoma cells)^[2]
Dosage:

125 mg/kg (1:1 molar ratio with β-cyclodextrin tetradecasulfate)
Administration:

s.c.; continuous infusion; 14 days (days 4 to 18 post-tumor implantation)
Result:

Produced a tumor growth delay of 0.6 days.
Reduced the CDDP-induced tumor growth delay from 4.5 days to 2.2 days.
Reduced the melphalan-induced tumor growth delay from 2.7 days to 1.1 days.
Increased the single-dose cyclophosphamide-induced tumor growth delay from 7.2 days to 16.2 days.
Increased the three-dose cyclophosphamide-induced tumor growth delay from 21.5 days to 36.8 days.
Increased the single-dose radiation-induced tumor growth delay from 6.2 days to 8.3 days.
Increased the fractionated radiation-induced tumor growth delay from 4.4 days to 7.1 days.
Did not alter the total number of lung metastases (mean 14.5) or the percentage of large (vascularized) metastases (69%) compared to untreated controls.
Did not alter the number of lung metastases produced by CDDP, melphalan, cyclophosphamide, or radiation.

Chemical Information

CAS. Nr. 53-02-1
Appearance Solid
Molecular Weight 366.49
Formel C₂₁H₃₄O₅
Color White to off-white
SMILES

C[C@@]12[C@](C(CO)=O)(O)CC[C@@]1([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])[C@@H](O)C2
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (136.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7286 mL

13.6429 mL

27.2859 mL

5 mM

0.5457 mL

2.7286 mL

5.4572 mL

10 mM

0.2729 mL

1.3643 mL

2.7286 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (3.41 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (3.41 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (3.41 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (739 KB)
- English - EN (739 KB)
- Français - FR (739 KB)
- Deutsch - DE (739 KB)
- Norwegian - NO (739 KB)
- Español - ES (739 KB)
- Swedish - SV (739 KB)
- Italian - IT (739 KB)
- Korean - KR (739 KB)
- Portuguese - PT (739 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Clark AF, et al. Inhibition of dexamethasone-induced cytoskeletal changes in cultured human trabecular meshwork cells by tetrahydrocortisol. Invest Ophthalmol Vis Sci. 1996;37(5):805-813. [Content Brief]

[2]. Teicher BA, et al. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma. Cancer Chemother Pharmacol. 1993;33(3):229-238. [Content Brief]

[3]. Sei-itsu Murota, et al. Effects of cortisol and tetrahydrocortisol on the cloned fibroblast derived from rat carrageenin granuloma. Biochemical Pharmacology. Volume 25, Issue 9, 1 May 1976.

[4]. Feng L, et al. Discovery of Natural Resorcylic Acid Lactones as Novel Potent Copper Ionophores Covalently Targeting PRDX1 to Induce Cuproptosis for Triple-Negative Breast Cancer Therapy. ACS Cent Sci. 2025 Feb 10;11(2):357-370. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7286 mL	13.6429 mL	27.2859 mL	68.2147 mL
	5 mM	0.5457 mL	2.7286 mL	5.4572 mL	13.6429 mL
	10 mM	0.2729 mL	1.3643 mL	2.7286 mL	6.8215 mL
	15 mM	0.1819 mL	0.9095 mL	1.8191 mL	4.5476 mL
	20 mM	0.1364 mL	0.6821 mL	1.3643 mL	3.4107 mL
	25 mM	0.1091 mL	0.5457 mL	1.0914 mL	2.7286 mL
	30 mM	0.0910 mL	0.4548 mL	0.9095 mL	2.2738 mL
	40 mM	0.0682 mL	0.3411 mL	0.6821 mL	1.7054 mL
	50 mM	0.0546 mL	0.2729 mL	0.5457 mL	1.3643 mL
	60 mM	0.0455 mL	0.2274 mL	0.4548 mL	1.1369 mL
	80 mM	0.0341 mL	0.1705 mL	0.3411 mL	0.8527 mL
	100 mM	0.0273 mL	0.1364 mL	0.2729 mL	0.6821 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Tetrahydrocortisol

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Lipid Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Food-Sourced Compound Library

Drug Metabolite Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Nuclear Receptor Compound Library

Pain-Related Compound Library

Animal-Sourced Natural Product Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Lipid Metabolite Compound Library

Steroid Hormones Library

Mass Spectrometry Natural Product Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tetrahydrocortisol

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Lipid Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Food-Sourced Compound Library

Drug Metabolite Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Nuclear Receptor Compound Library

Pain-Related Compound Library

Animal-Sourced Natural Product Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Lipid Metabolite Compound Library

Steroid Hormones Library

Mass Spectrometry Natural Product Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tetrahydrocortisol Related Classifications

HY-129630 Related Classifications